论文部分内容阅读
目的探讨清除终末期肾脏疾病(ESRD)患者血清蓄积的糖基化终产物-肽(AGE-P)的最佳透析方式。方法 78例ESRD患者随机均分为三组,每组26例,分别予聚砜膜(PS)F6、双醋酸纤维膜(CA)150、血仿膜(HE)行低通量血液透析。随后,78例患者中再随机选取66例患者均分为三组,每组22例,分别给予PSF6低通量血液透析、PSF60高通量血液透析、PSF60血液滤过;血液透析及血液滤过前后采集血清,应用流动注射分析法检测AGE-P。结果应用PSF6、CA150、HE行低通量血液透析三组间血清AGE-P下降率无显著性差异(P>0.05)。高通量血液透析及血液滤过后血清AGE-P下降率明显高于低通量血液透析(P<0.01)。结论高通量血液透析和血液滤过对AGE-P的清除效果优于低通量血液透析。
Objective To investigate the optimal dialysis method of AGE-P in the serum of patients with end-stage renal disease (ESRD). Methods A total of 78 patients with ESRD were randomly divided into three groups with 26 cases in each group. The patients were given polysulfone membrane (PS) F6, diacetate acetate (CA) 150 and hemodialysis membrane respectively. Subsequently, of the 78 patients randomized 66 patients were divided into three groups of 22 patients, respectively, given PSF6 low-pass hemodialysis, PSF60 high-pass hemodialysis, PSF60 hemofiltration; hemodialysis and hemofiltration Serum was collected before and after, and AGE-P was detected by flow injection analysis. Results There was no significant difference in the decreasing rate of serum AGE-P between the three groups using PSF6, CA150 and HE in low-flux hemodialysis patients (P> 0.05). The decrease rate of serum AGE-P after high-flux hemodialysis and hemofiltration was significantly higher than that of low-dose hemodialysis (P <0.01). Conclusion High-throughput hemodialysis and hemofiltration are better than low-throughput hemodialysis in removing AGE-P.